{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:15:45Z","timestamp":1783296945147,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The renin\u2013angiotensin\u2013aldosterone system regulates blood pressure and is influenced by antihypertensive therapy. We examined plasma aldosterone concentration (PAC), plasma renin activity (PRA), and clinical characteristics in untreated hypertensive patients without primary aldosteronism, followed for 3 years. Among 456 newly diagnosed patients, 397 (219 males, 178 females) were analyzed after excluding those with low blood pressure, suspected primary aldosteronism, or renovascular hypertension. PAC and PRA were measured at baseline, and clinic blood pressure was monitored at 3 months, 1 year, and 3 years. A high PAC\/PRA ratio (&gt;200) was found in 19.6% of patients and was significantly associated with female sex (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) and higher serum sodium (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0004). PAC did not differ between groups, but PRA was markedly lower in the high PAC\/PRA group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001). Multivariate analysis identified female sex as the only independent predictor (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001), with prevalence rates of 29.8% in females and 11.4% in males. In females, PAC\/PRA correlated positively with sodium, while PRA correlated negatively, relationships not observed in males. Mineralocorticoid receptor antagonists (MRAs) were used as first-line therapy in patients with high PAC\/PRA. Their blood pressure declined from 159\/95\u2009mmHg at baseline to 137\/80, 135\/78, and 133\/77\u2009mmHg at 3 months, 1 year, and 3 years, respectively. In the normal group, values were 159\/96, 142\/81, 138\/77, and 136\/77\u2009mmHg, with greater systolic reduction at 3 months in the high PAC\/PRA group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03). We identified gender differences in the renin\u2013aldosterone\u2013sodium system. MRAs effectively reduced blood pressure in patients with relatively low PRA levels.\n                  <\/jats:p>","DOI":"10.1038\/s41440-026-02666-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:43:55Z","timestamp":1779259435000},"page":"2059-2071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma aldosterone concentration and plasma renin activity in untreated hypertensive patients: gender differences and therapeutic implications"],"prefix":"10.1038","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4499-7522","authenticated-orcid":false,"given":"Masafumi","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2666_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.peptides.2010.02.008","volume":"31","author":"S Nagata","year":"2010","unstructured":"Nagata S, Kato J, Kuwasako K, Kitamura K. Plasma and tissue levels of proangiotensin-12 and components of the renin\u2013angiotensin system following low- or high-salt feeding in rats. Peptides. 2010;31:889\u201392.","journal-title":"Peptides"},{"key":"2666_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/hr.2013.69","volume":"36","author":"T Shimosawa","year":"2013","unstructured":"Shimosawa T. Salt, the renin\u2013angiotensin\u2013aldosterone system and resistant hypertension. Hypertens Res. 2013;36:657\u201360.","journal-title":"Hypertens Res"},{"key":"2666_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/bmj.1.5854.650","volume":"1","author":"JJ Brown","year":"1973","unstructured":"Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JIS, et al. Recurrent hyperkalaemia due to selective aldosterone deficiency: correction by angiotensin infusion. Br Med J. 1973;1:650\u201354.","journal-title":"Br Med J"},{"key":"2666_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S0002-9149(99)00091-0","volume":"83","author":"H Yasue","year":"1999","unstructured":"Yasue H, Ogawa H, Tanaka H, Miyazaki S, Hattori R, Saito M, et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction: the Japanese Antiplatelets Myocardial Infarction Study (JAMIS). Am J Cardiol. 1999;83:1308\u201313.","journal-title":"Am J Cardiol"},{"key":"2666_CR5","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/S0140-6736(16)31134-5","volume":"388","author":"MH Olsen","year":"2016","unstructured":"Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure: the Lancet Commission on hypertension. Lancet. 2016;388:2665\u2013712.","journal-title":"Lancet"},{"key":"2666_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2666_CR7","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/s41440-025-02331-8","volume":"48","author":"Y Ohya","year":"2025","unstructured":"Ohya Y, Sakima A, Arima H, Fukami A, Furuhashi M, Ishida M, et al. Key highlights of the Japanese Society of Hypertension Guidelines for the Management of Elevated Blood Pressure and Hypertension 2025 (JSH 2025). Hypertens Res. 2025;48:2500\u201311.","journal-title":"Hypertens Res"},{"key":"2666_CR8","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000257","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2025;82:e212\u2013e316.","journal-title":"Hypertension"},{"key":"2666_CR9","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"2666_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.1979.03290280031022","volume":"241","author":"JH Laragh","year":"1979","unstructured":"Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA. 1979;241:151\u20136.","journal-title":"JAMA"},{"key":"2666_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJM197203022860901","volume":"286","author":"HR Brunner","year":"1972","unstructured":"Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441\u20139.","journal-title":"N Engl J Med"},{"key":"2666_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/0003-4819-87-5-596","volume":"87","author":"JR Mitchell","year":"1977","unstructured":"Mitchell JR, Taylor AA, Pool JL, Lake CR, Rollins DE, Bartter FC. Renin-aldosterone profiling in hypertension. Ann Intern Med. 1977;87:306\u201312.","journal-title":"Ann Intern Med"},{"key":"2666_CR13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892\u20136.","journal-title":"Hypertension"},{"key":"2666_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.7326\/0003-4819-84-6-639","volume":"85","author":"NM Kaplan","year":"1976","unstructured":"Kaplan NM, Kem DC, Holland OB. The intravenous furosemide test: a simple way to evaluate renin responsiveness. Ann Intern Med. 1976;85:639\u201345.","journal-title":"Ann Intern Med"},{"key":"2666_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/01.CIR.95.1.39","volume":"95","author":"H Schunkert","year":"1997","unstructured":"Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kurzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the renin\u2013angiotensin system in postmenopausal women. Circulation. 1997;95:39\u201345.","journal-title":"Circulation"},{"key":"2666_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1161\/01.HYP.37.5.1199","volume":"37","author":"JF Reckelhoff","year":"2001","unstructured":"Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199\u2013208.","journal-title":"Hypertension"},{"key":"2666_CR17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1919\u201328.","journal-title":"J Hypertens"},{"key":"2666_CR18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","volume":"74","author":"GP Rossi","year":"2019","unstructured":"Rossi GP. Primary aldosteronism. J Am Coll Cardiol. 2019;74:2799\u2013811.","journal-title":"J Am Coll Cardiol"},{"key":"2666_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1507\/endocrj.KR-105","volume":"54","author":"T Nishikawa","year":"2007","unstructured":"Nishikawa T, Saito J, Omura M. Prevalence of primary aldosteronism: should we screen for primary aldosteronism before treating patients with medication?. Endocr J. 2007;54:487\u201395.","journal-title":"Endocr J"},{"key":"2666_CR20","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1210\/jc.2006-1154","volume":"91","author":"ED Szmuilowicz","year":"2006","unstructured":"Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN, et al. Progesterone increases aldosterone levels during the luteal phase of the menstrual cycle. J Clin Endocrinol Metab. 2006;91:3981\u201387.","journal-title":"J Clin Endocrinol Metab"},{"key":"2666_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/ajh.2012.21","volume":"25","author":"PJ Hofmann","year":"2012","unstructured":"Hofmann PJ, Michaelis M, G\u00f6tz F, Bartel C, Kienitz T, Quinkler M. Flutamide increases aldosterone levels in gonadectomized male but not female Wistar rats. Am J Hypertens. 2012;25:697\u2013703.","journal-title":"Am J Hypertens"},{"key":"2666_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ygcen.2017.11.008","volume":"259","author":"RV Carsia","year":"2018","unstructured":"Carsia RV, McIlroy PJ, John-Alder HB. Modulation of adrenal steroidogenesis by testosterone in the lizard Coleonyx elegans. Gen Comp Endocrinol. 2018;259:93\u2013103.","journal-title":"Gen Comp Endocrinol"},{"key":"2666_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.06.009","volume":"203","author":"ME Moss","year":"2019","unstructured":"Moss ME, Carvajal B, Jaffe IZ. The endothelial mineralocorticoid receptor: contributions to sex differences in cardiovascular disease. Pharmacol Ther. 2019;203:107387.","journal-title":"Pharmacol Ther"},{"key":"2666_CR24","doi-asserted-by":"publisher","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","volume":"269","author":"H Hatakeyama","year":"1994","unstructured":"Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto. H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269:24316\u201320.","journal-title":"J Biol Chem"},{"key":"2666_CR25","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1006\/jmcc.1999.0963","volume":"31","author":"SH Slight","year":"1999","unstructured":"Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids and cardiovascular tissue. Mol Cell Cardiol. 1999;31:1175\u201384.","journal-title":"Mol Cell Cardiol"},{"key":"2666_CR26","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","volume":"99","author":"JS Silvestre","year":"1999","unstructured":"Silvestre JS, Heymes C, Oub\u00e9na\u00efssa A, Robert V, Aupetit-Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694\u2013701.","journal-title":"Circulation"},{"key":"2666_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1161\/01.HYP.0000015905.27598.E9","volume":"39","author":"N Yamamoto","year":"2002","unstructured":"Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M, et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension. 2002;39:958\u201362.","journal-title":"Hypertension"},{"key":"2666_CR28","first-page":"CD004022","volume":"1","author":"G J\u00fcrgens","year":"2004","unstructured":"J\u00fcrgens G, Graudal NA. Effects of low- versus high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev. 2004;1:CD004022.","journal-title":"Cochrane Database Syst Rev"},{"key":"2666_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ajh\/hpaa208","volume":"34","author":"T Dudenbostel","year":"2021","unstructured":"Dudenbostel T, Li P, Calhoun DA. Paradoxical increase of 24-hour urinary aldosterone levels in obese patients with resistant hypertension on a high-salt diet. Am J Hypertens. 2021;34:600\u20138.","journal-title":"Am J Hypertens"},{"key":"2666_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2019.11.006","volume":"31","author":"A Feraco","year":"2020","unstructured":"Feraco A, Marzolla V, Scuteri A, Armani A, Caprio M. Mineralocorticoid receptors in metabolic syndrome: from physiology to disease. Trends Endocrinol Metab. 2020;31:205\u201317.","journal-title":"Trends Endocrinol Metab"},{"key":"2666_CR31","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1210\/en.2005-1244","volume":"147","author":"M Yamamuro","year":"2006","unstructured":"Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology. 2006;147:1314\u201321.","journal-title":"Endocrinology"},{"key":"2666_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1507\/endocrj.EJ16-0304","volume":"63","author":"T Nishikawa","year":"2016","unstructured":"Nishikawa T, Omura M, Kawaguchi M, Takatsu A, Satoh F, Ito S, et al. Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement. Endocr J. 2016;63:1065\u201380.","journal-title":"Endocr J"},{"key":"2666_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2195796","volume":"2019","author":"T Li","year":"2019","unstructured":"Li T, Ma Y, Zhang Y, et al. Feasibility of screening for primary aldosteronism using the aldosterone-to-direct renin concentration ratio derived from chemiluminescent immunoassay. Int J Hypertens. 2019;2019:2195796.","journal-title":"Int J Hypertens"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02666-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02666-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:02:58Z","timestamp":1783296178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02666-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2666"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02666-w","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Kumamoto University Hospital (approval no. 1619). Informed consent was obtained either in writing or via the opt-out method. The study protocol was publicly announced at Kumamoto University and on our website (\n                      \n                      ). Patients and medical institutions were free to withdraw from the study at any time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}